Laurel Oak Wealth Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$545K Buy
22,641
+365
+2% +$9.55K 0.08% 187
2026
Q1
$626K Sell
22,276
-86
-0.4% -$2.29K 0.11% 158
2025
Q4
$557K Buy
+22,362
New +$564K 0.09% 172

Other funds holding PFE

Laurel Oak Wealth Management's PFE Position: Q2 2026 in Review

Laurel Oak Wealth Management increased its Pfizer (PFE) stake by 1.6% in Q2 2026, buying an estimated $9.55K and bringing the position to 22,641 shares worth $545K. The position accounts for 0.08% of the portfolio, ranked #187.

Laurel Oak Wealth Management first reported a position in PFE in Q4 2025 and has held it in 3 quarters since. The position peaked at $626K in Q1 2026. 2,820 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Laurel Oak Wealth Management held 22,641 shares of Pfizer worth $545K as of Q2 2026.
  • Laurel Oak Wealth Management bought 365 Pfizer shares in Q2 2026, an estimated $9.55K.
  • Pfizer made up 0.08% of Laurel Oak Wealth Management's portfolio in Q2 2026, its #187 holding.
  • Laurel Oak Wealth Management first reported a position in Pfizer in Q4 2025 and has held it in 3 quarters since.
  • Laurel Oak Wealth Management's Pfizer position peaked at $626K in Q1 2026.
  • 2,820 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Laurel Oak Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.